Abstract
Over the past decade, the promising results of UPSIs (UPS inhibitors) in eliciting apoptosis in various cancer cells, and the approval of the first UPSI (Bortezomib/Velcade/PS-341) for the treatment of multiple myeloma have raised interest in assessing the death program activated upon proteasomal blockage. Several reports indicate that UPSIs stimulate apoptosis in malignant cells by operating at multiple levels, possibly by inducing different types of cellular stress. Normally cellular stress signals converge on the core elements of the apoptotic machinery to trigger the cellular demise. In addition to eliciting multiple stresses, UPSIs can directly operate on the core elements of the apoptotic machinery to control their abundance. Alterations in the relative levels of anti and pro-apoptotic factors can render cancer cells more prone to die in response to other anti-cancer treatments. Aim of the present review is to discuss those core elements of the apoptotic machinery that are under the control of the UPS.
Keywords: Apoptosis, caspases, IAP, IBM, bortezomib, Bcl-2, mitochondria, death receptors, apoptosome, p53
Current Molecular Pharmacology
Title: Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?
Volume: 1
Author(s): Claudio Brancolini
Affiliation:
Keywords: Apoptosis, caspases, IAP, IBM, bortezomib, Bcl-2, mitochondria, death receptors, apoptosome, p53
Abstract: Over the past decade, the promising results of UPSIs (UPS inhibitors) in eliciting apoptosis in various cancer cells, and the approval of the first UPSI (Bortezomib/Velcade/PS-341) for the treatment of multiple myeloma have raised interest in assessing the death program activated upon proteasomal blockage. Several reports indicate that UPSIs stimulate apoptosis in malignant cells by operating at multiple levels, possibly by inducing different types of cellular stress. Normally cellular stress signals converge on the core elements of the apoptotic machinery to trigger the cellular demise. In addition to eliciting multiple stresses, UPSIs can directly operate on the core elements of the apoptotic machinery to control their abundance. Alterations in the relative levels of anti and pro-apoptotic factors can render cancer cells more prone to die in response to other anti-cancer treatments. Aim of the present review is to discuss those core elements of the apoptotic machinery that are under the control of the UPS.
Export Options
About this article
Cite this article as:
Brancolini Claudio, Inhibitors of the Ubiquitin-Proteasome System and the Cell Death Machinery: How Many Pathways are Activated?, Current Molecular Pharmacology 2008; 1 (1) . https://dx.doi.org/10.2174/1874467210801010024
DOI https://dx.doi.org/10.2174/1874467210801010024 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mechanisms of Neuronal Damage and Neuroprotection Underlying Ischemia/Reperfusion Injury after Physical Exercise
Current Drug Targets Microenvironment and Brain Tumor Stem Cell Maintenance: Impact of the Niche
Anti-Cancer Agents in Medicinal Chemistry The Combination of FDG PET/CT and Contrast Enhanced CT in the Evaluation of Recurrent Pancreatic Carcinoma and Cholangiocarcinoma
Current Medical Imaging The Mechanism in Gastric Cancer Chemoprevention by Allicin
Anti-Cancer Agents in Medicinal Chemistry Modulation of Human Keratinocyte Responses to Solar UV by Plant Polyphenols As a Basis for Chemoprevention of Non-Melanoma Skin Cancers
Current Medicinal Chemistry Platelet-Derived Chemokines in Atherogenesis: What’s New?
Current Vascular Pharmacology Polymorphism in Endothelin-1 Gene: An Overview
Current Clinical Pharmacology Gender Differences in the Antioxidant Response to Oxidative Stress in Experimental Brain Tumors
Current Cancer Drug Targets Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy
Current Molecular Pharmacology Prognostic Biomarkers of Cutaneous Malignancies – Serological, Immunohistochemical and Proteomic Approaches
Current Cancer Therapy Reviews NEDD4: A Promising Target for Cancer Therapy
Current Cancer Drug Targets Notch Inhibitors as a New Tool in the War on Cancer: A Pathway to Watch
Current Pharmaceutical Biotechnology p16<sup>INK4</sup> as a Biomarker in Oropharyngeal Squamous Cell Carcinoma
Recent Patents on Biomarkers Epigenetic Regulation in Particulate Matter-Mediated Cardiopulmonary Toxicities: A Systems Biology Perspective
Current Pharmacogenomics and Personalized Medicine Database Construction and Peptide Identification Strategies for Proteogenomic Studies on Sequenced Genomes
Current Topics in Medicinal Chemistry Subject Index To Volume 1
Current Bioinformatics Marizomib, a Proteasome Inhibitor for All Seasons: Preclinical Profile and a Framework for Clinical Trials
Current Cancer Drug Targets MDM2 Inhibitors for Pancreatic Cancer Therapy
Mini-Reviews in Medicinal Chemistry Clinical Uses of Melatonin: Evaluation of Human Trials
Current Medicinal Chemistry Novel Nanolipoidal Systems for the Management of Skin Cancer
Recent Patents on Drug Delivery & Formulation